Akebia reports Q4 EPS (10c) vs 0c last year

Reports Q4 revenue $46.497M, consensus $37.36M. Commenting on the Vafseo launch, John P. Butler, Chief Executive Officer of Akebia (AKBA) said: “We believe Vafseo can be a new standard of care for the treatment of anemia due to chronic kidney disease. The U.S. product launch is underway and our initial execution across multiple initiatives demonstrates we are making significant early progress towards that goal for dialysis patients. We launched Vafseo with commercial supply contracts in place with dialysis organizations caring for nearly 100% of dialysis patients in the U.S., which we believe is the first time a drug with Transitional Drug Add-on Payment Adjustment reimbursement has done so. We are very pleased with the early results and expect to generate Vafseo net product revenue of approximately $10-$11 million in the first quarter of 2025.”